Citation: | Chenxi LI, Zhuocen ZHA, Na LI, Lin LUO, Yang YANG, Wenlin CHEN. Selection of Intensive Adjuvant Therapy for Triple-positive Breast Cancer[J]. Journal of Kunming Medical University, 2023, 44(10): 180-188. doi: 10.12259/j.issn.2095-610X.S20231020 |
[1] |
Siegel R L,Miller K D,Fuchs H E,et al. Cancer statistics,2022[J]. CA:A Cancer Journal for Clinicians,2022,72(1):7-33. doi: 10.3322/caac.21708
|
[2] |
Osborne C K,Schiff R. Mechanisms of endocrine resistance in breast cancer[J]. Annual Review of Medicine,2011,62(1):233-247. doi: 10.1146/annurev-med-070909-182917
|
[3] |
Konecny G,Pauletti G,Pegram M,et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone eceptor-positive primary breast cancer[J]. JNCI Journal of the National Cancer Institute,2003,95(2):142-153. doi: 10.1093/jnci/95.2.142
|
[4] |
Brandão M,Caparica R,Malorni L,et al. What is the real impact of estrogen receptor status on the prognosis and treatment of HER2-positive early breast cancer?[J]. Clinical Cancer Research,2020,26(12):2783-2788. doi: 10.1158/1078-0432.CCR-19-2612
|
[5] |
Zhao S,Liu X Y,Jin X,et al. Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive,progesterone receptor-positive,and HER2-positive breast cancer[J]. Theranostics,2019,9(17):4935-4945. doi: 10.7150/thno.35730
|
[6] |
Refae S,Pistilli B,Delaloge S. Extended anti-HER2 therapy in early breast cancer: Longer beats shorter?[J]. Current Opinion in Oncology,2016,28(6):469-475. doi: 10.1097/CCO.0000000000000325
|
[7] |
Gianni L,Eiermann W,Semiglazov V,et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort[J]. The Lancet Oncology,2014,15(6):640-647. doi: 10.1016/S1470-2045(14)70080-4
|
[8] |
Baselga J,Bradbury I,Eidtmann H,et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised,open-label,multicentre,phase 3 trial[J]. The Lancet,2012,379(9816):633-640. doi: 10.1016/S0140-6736(11)61847-3
|
[9] |
Schneeweiss A,Chia S,Hickish T,et al. Long-term efficacy analysis of the randomised,phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer[J]. European Journal of Cancer,2018,89:27-35. doi: 10.1016/j.ejca.2017.10.021
|
[10] |
Dhillon S. Neratinib in early-stage breast cancer: A profile of its use in the EU[J]. Clinical Drug Investigation,2019,39(2):221-229. doi: 10.1007/s40261-018-0741-2
|
[11] |
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials[J]. Lancet,2005,365(9472):1687-1717. doi: 10.1016/S0140-6736(05)66544-0
|
[12] |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南2022[M]. 北京: 人民卫生出版社, 2022: 29, 48-49, 65, 86.
|
[13] |
Piccart M,Procter M,Fumagalli D,et al. Adjuvant pertuzumab and trastuzumab in early HER2-Positive breast cancer in the APHINITY trial: 6 years’ follow-up[J]. Journal of Clinical Oncology,2021,39(13):1448-1457. doi: 10.1200/JCO.20.01204
|
[14] |
Giuliano M,Trivedi M V,Schiff R. Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications[J]. Breast Care,2013,8(4):256-262. doi: 10.1159/000354253
|
[15] |
Cotrim C Z,Fabris V,Doria M L,et al. Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells[J]. Oncogene,2013,32(19):2390-2402. doi: 10.1038/onc.2012.261
|
[16] |
Wang Y C,Morrison G,Gillihan R,et al. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers - role of estrogen receptor and HER2 reactivation[J]. Breast Cancer Research,2011,13(6):R121. doi: 10.1186/bcr3067
|
[17] |
Giuliano M,Hu H,Wang Y C,et al. Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy[J]. Clinical Cancer Research,2015,21(17):3995-4003. doi: 10.1158/1078-0432.CCR-14-2728
|
[18] |
Schettini F,Buono G,Cardalesi C,et al. Hormone receptor/human epidermal growth factor receptor 2-positive breast cancer: Where we are now and where we are going[J]. Cancer Treatment Reviews,2016,46:20-26. doi: 10.1016/j.ctrv.2016.03.012
|
[19] |
Fox E M,Andrade J,Shupnik M A. Novel actions of estrogen to promote proliferation: Integration of cytoplasmic and nuclear pathways[J]. Steroids,2009,74(7):622-627. doi: 10.1016/j.steroids.2008.10.014
|
[20] |
Kato S. Estrogen receptor-mediated cross-talk with growth factor signaling pathways[J]. Breast Cancer,2001,8(1):3-9. doi: 10.1007/BF02967472
|
[21] |
Yarden R I,Wilson M A,Chrysogelos S A. Estrogen suppression of EGFR expression in breast cancer cells: A possible mechanism to modulate growth[J]. Journal of Cellular Biochemistry,2001,81(S36):232-246. doi: 10.1002/jcb.1142
|
[22] |
von Minckwitz G,Huang C S,Mano M S,et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer[J]. New England Journal of Medicine,2019,380(7):617-628. doi: 10.1056/NEJMoa1814017
|
[23] |
Goel S,Pernas S,Tan-Wasielewski Z,et al. Ribociclib plus trastuzumab in advanced HER2-positive breast cancer: results of a phase 1b/2 trial[J]. Clinical Breast Cancer,2019,19(6):399-404. doi: 10.1016/j.clbc.2019.05.010
|
[24] |
Martin M,Holmes F A,Ejlertsen B,et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised,double-blind,placebo-controlled,phase 3 trial[J]. The Lancet Oncology,2017,18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9
|
[25] |
Chan A,Delaloge S,Holmes F A,et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre,randomised,double-blind,placebo-controlled,phase 3 trial[J]. The Lancet Oncology,2016,17(3):367-377. doi: 10.1016/S1470-2045(15)00551-3
|
[26] |
Cognetti F,Di Cosimo S,Bruzzi P,et al. 139P HER2+/HR+ breast cancer patients at high risk of relapse derive benefit from extended adjuvant treatment with neratinib: An exploratory analysis from ExteNET study[J]. Annals of Oncology,2021,32:S420.
|
[27] |
Yu K,Cai Y,Wu S,et al. Estrogen receptor‐low breast cancer: Biology chaos and treatment paradox[J]. Cancer Communications,2021,41(10):968-980. doi: 10.1002/cac2.12191
|
[28] |
Johnston S R D,Harbeck N,Hegg R,et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+,HER2−,node-positive,high-risk,early breast cancer (monarchE)[J]. Journal of Clinical Oncology,2020,38(34):3987-3998. doi: 10.1200/JCO.20.02514
|
[29] |
Hua X,Bi X W,Zhao J-L,et al. Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for patients with hormone receptor–positive and HER2-positive metastatic Breast Cancer (SYSUCC-002)[J]. Clinical Cancer Research,2022,28(4):637-645. doi: 10.1158/1078-0432.CCR-21-3435
|
[30] |
Rimawi M,Ferrero J-M,de la Haba-Rodriguez J,et al. First-line trastuzumab plus an aromatase inhibitor,with or without pertuzumab,in human epidermal growth factor receptor 2–positive and hormone receptor–positive metastatic or locally advanced breast cancer (PERTAIN): A randomized,open-label phase II trial[J]. Journal of Clinical Oncology,2018,36(28):2826-2835. doi: 10.1200/JCO.2017.76.7863
|
[31] |
Johnston S R D,Hegg R,Im S-A,et al. Phase III,randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-Positive,hormone receptor–positive metastatic breast cancer: updated results of ALTERNATIVE[J]. Journal of Clinical Oncology,2021,39(1):79-89. doi: 10.1200/JCO.20.01894
|
[32] |
Ciruelos E,Villagrasa P,Pascual T,et al. Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial[J]. Clinical Cancer Research,2020,26(22):5820-5829. doi: 10.1158/1078-0432.CCR-20-0844
|
[33] |
Zhang J,Meng Y,Wang B,et al. Dalpiciclib combined with pyrotinib and letrozole in women with HER2-positive,hormone receptor-positive metastatic breast cancer (LORDSHIPS): A phase Ib study[J]. Frontiers in Oncology,2022,12:775081. doi: 10.3389/fonc.2022.775081
|
[34] |
Spring L M,Clark S L,Li T,et al. Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer[J]. npj Breast Cancer,2021,7(1):103. doi: 10.1038/s41523-021-00311-y
|
[35] |
Haley B,Batra K,Sahoo S,et al. A phase I/Ib trial of PD 0332991 (palbociclib) and T-DM1 in HER2-positive advanced breast cancer after trastuzumab and taxane therapy[J]. Clinical Breast Cancer,2021,21(5):417-424. doi: 10.1016/j.clbc.2021.03.005
|
[36] |
André F,Nadal J C,Denys H,et al. LBA18 Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+,HER2+ advanced breast cancer (monarcHER): A randomized,open-label,phase II trial[J]. Annals of Oncology,2022,33:S1386-S1387.
|
[37] |
Tolaney S M,Wardley A M,Zambelli S,et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive,HER2-positive advanced breast cancer (monarcHER): A randomised,open-label,phase 2 trial[J]. The Lancet Oncology,2020,21(6):763-775. doi: 10.1016/S1470-2045(20)30112-1
|
[38] |
Johnston S,Pippen J,Pivot X,et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor–positive metastatic breast cancer[J]. Journal of Clinical Oncology,2009,27(33):5538-5546. doi: 10.1200/JCO.2009.23.3734
|
[39] |
Huober J,Fasching P A,Barsoum M,et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive,hormone-receptor-positive metastatic breast cancer-results of the eLEcTRA trial[J]. The Breast,2012,21(1):27-33. doi: 10.1016/j.breast.2011.07.006
|
[40] |
Kaufman B,Mackey J R,Clemens M R,et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2–positive,hormone receptor–positive metastatic breast cancer: Results from the randomized phase III TAnDEM study[J]. Journal of Clinical Oncology,2009,27(33):5529-5537. doi: 10.1200/JCO.2008.20.6847
|
[41] |
Lv H, Yan M, Jiang Z. Recent advances in the treatment of hormone receptor-positive/human epidermal growth factor 2-positive advanced breast cancer[J]. Therapeutic Advances in Medical Oncology, 2021, 13: 175883592110133.
|
[42] |
Yan C,Wei H,Minjuan Z,et al. The mTOR inhibitor rapamycin synergizes with a fatty acid synthase inhibitor to induce cytotoxicity in ER/HER2-positive breast cancer cells[J]. D Calvisi PLoS ONE,2014,9(5):e97697. doi: 10.1371/journal.pone.0097697
|
[43] |
Hurvitz S A,Andre F,Jiang Z,et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): A phase 3,randomised,double-blind,multicentre trial[J]. The Lancet Oncology,2015,16(7):816-829. doi: 10.1016/S1470-2045(15)00051-0
|
[44] |
André F,O’Regan R,Ozguroglu M,et al. Everolimus for women with trastuzumab-resistant,HER2-positive,advanced breast cancer (BOLERO-3): A randomised,double-blind,placebo-controlled phase 3 trial[J]. The Lancet Oncology,2014,15(6):580-591. doi: 10.1016/S1470-2045(14)70138-X
|
[45] |
Mcdermott M S J,Canonici A,Ivers L,et al. Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells[J]. International Journal of Oncology,2017,50(6):2221-2228. doi: 10.3892/ijo.2017.3976
|
[1] | Jiong LUO, Jifeng SU, Lin WANG. Diagnosis and Treatment of 11 Cases of Primary Hepatic Neuroendocrine Tumors. Journal of Kunming Medical University, 2024, 45(11): 103-109. doi: 10.12259/j.issn.2095-610X.S20241128 |
[2] | Wenjuan SONG, Xuejuan MA, Yue SUN, Ying GU, Yujia YE, Shumo LI, Fei GE, Liping LIU, Yue ZHAO, Yu WANG. Evaluation of Cardiotoxicity in Trastuzumab Treatment of Breast Cancer Using Three-dimensional Speckle Tracking Echocardiography. Journal of Kunming Medical University, 2023, 44(2): 108-112. doi: 10.12259/j.issn.2095-610X.S20230217 |
[3] | Lu LI, Yunfen TIAN. Research Progress on Intestinal Microflora and Non-alcoholic Fatty Liver Disease in Children. Journal of Kunming Medical University, 2023, 44(7): 148-155. doi: 10.12259/j.issn.2095-610X.S20230708 |
[4] | Ting LI, Wei-Hua GUO. Research Progress of Glycolytic Reprogramming in Oral Squamous Cell Carcinoma. Journal of Kunming Medical University, 2023, 44(6): 155-161. doi: 10.12259/j.issn.2095-610X.S20230611 |
[5] | Xiaohua LU, Hongxin YUAN. The Analysis of the Correlation between BTLA,CTLA-4 Gene Polymorphisms and the Efficacy and Prognosis of TACE Combined Targeted Therapy for Liver Cancer. Journal of Kunming Medical University, 2023, 44(9): 126-135. doi: 10.12259/j.issn.2095-610X.S20230927 |
[6] | Pingbo XIE, Mingsheng LIU, Hongqing ZHOU, Shaomei WU, Tao SHAO, Feng GUO. Effect Analysis of Transurethral Resection of Prostate Combined with Endocrine Therapy for Advanced Prostate Cancer. Journal of Kunming Medical University, 2023, 44(12): 46-50. doi: 10.12259/j.issn.2095-610X.S20231208 |
[7] | Qiao LUO, Hong SHI, Shaobo WANG. Role of α7-nicotinic Acetylcholine Receptor in Occurrence,Development and Therapy of Lung Cancer. Journal of Kunming Medical University, 2022, 43(2): 145-149. doi: 10.12259/j.issn.2095-610X.S20220226 |
[8] | Wen-jing SUN, Man-ting HU, Na LI, Fei GE, Wen-lin CHEN, Yang LIU. Progress in Clinical Research on Drug Resistance and Reversal of Endocrine Therapy in Breast Cancer. Journal of Kunming Medical University, 2021, 42(7): 143-149. doi: 10.12259/j.issn.2095-610X.S20210724 |
[9] | Chang-xian CHEN, Li-ju ZHANG, Xiao-ming JIANG, Zhen-yong ZHANG, Wei-jun LIU. Advances in Treatment of Colorectal Neuroendocrine Tumors. Journal of Kunming Medical University, 2020, 41(12): 155-159. doi: 10.12259/j.issn.2095-610X.S20201242 |
[10] | Zhu Zhong Shan , Yan Wen Hui , Li Xiao Bing , Yang Zhou , Bai Peng . Driver Genes Mutation and Survival Analysis in 200 Patients with Pulmonary Adenocarcinoma Brain Metastasis. Journal of Kunming Medical University, 2018, 39(08): 47-50. |
[11] | Zhu Sheng Zhang , Lu Jian Bo , Wang Jing Ye , Li Ru Yi , Jiang Qiong , He Jin Song , Li Meng . Experimental Study on Neuroendocrine Differentiation of Colon Cancer Cell Line HCT-116 Induced by Epidermal Growth Factor. Journal of Kunming Medical University, 2017, 38(07): 45-49. |
[12] | Li Zhuo Lin . Assessment of Locally Advanced Breast Cancer Response to Neoadjuvant Chemotherapy with Diffusion weighted MRI. Journal of Kunming Medical University, |
[13] | Li Ming . The Current Situation of Research and Treatment on Male Breast Cancer. Journal of Kunming Medical University, |
[14] | Shang Xue Qin . . Journal of Kunming Medical University, |
[15] | Zhang Ming . . Journal of Kunming Medical University, |
[16] | Wang Jian Kui . . Journal of Kunming Medical University, |
[17] | Min Xiao Hong . . Journal of Kunming Medical University, |
[18] | Liu Peng Jie . . Journal of Kunming Medical University, |
[19] | Xu Ke Dong . . Journal of Kunming Medical University, |
[20] | Chen Xian Yu . . Journal of Kunming Medical University, |